Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Nov 30;17(11):9260-9262.
doi: 10.21037/jtd-2025-1472. Epub 2025 Nov 21.

Immune checkpoint inhibitors for advanced non-small cell lung cancer with poor performance status or older patients

Naoki Furuya  1
Affiliations
Editorial

Immune checkpoint inhibitors for advanced non-small cell lung cancer with poor performance status or older patients

Naoki Furuya. J Thorac Dis. .
No abstract available

Keywords: Immune checkpoint inhibitor (ICI); ipilimumab; nivolumab; non-small cell lung cancer (NSCLC); poor performance status (poor PS).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-1472/coif). The author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Treatment options of poor PS NSCLC based on the etiology PS decline and individual patients’ conditions. PS decline may result from cancer activity as well as comorbidities, age-related organ dysfunction, and nutritional status. Treatment options should be selected based on the etiology of PS decline and patient-specific factors, incorporating CGA, ACP, SDM, optimization of drug dose, treatment schedules, and supportive care. ACP, advance care planning; BSC, best supportive care; CGA, comprehensive geriatric assessment; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DTX, docetaxel; GEM, gemcitabine; ICI, immune checkpoint inhibitor; ILD, interstitial lung disease; NSCLC, non-small cell carcinoma; PS, performance status; SDM, shared decision making; VNR, vinorelbine.
See this image and copyright information in PMC

Comment on

References

    1. Léna H, Greillier L, Cropet C, et al. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study. Lancet Respir Med 2025;13:141-52. 10.1016/S2213-2600(24)00264-9 - DOI - PubMed
    1. Owen DH, Halmos B, Puri S, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1. J Clin Oncol 2025;43:e45-58. 10.1200/JCO-25-01062 - DOI - PubMed
    1. ESMO Living Guideline. Non-Oncogene-Addicted Metastatic NSCLC. Available online: https://www.esmo.org/guidelines/living-guidelines/esmo-living-guideline-...
    1. Brahmer JR, Lee JS, Ciuleanu TE, et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J Clin Oncol 2023;41:1200-12. 10.1200/JCO.22.01503 - DOI - PMC - PubMed
    1. Furuya N, Nishino M, Wakuda K, et al. Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody. Thorac Cancer 2021;12:613-8. 10.1111/1759-7714.13824 - DOI - PMC - PubMed